Searchable abstracts of presentations at key conferences in endocrinology

ea0026p445 | Thyroid (non cancer) | ECE2011

Thyroid function and mortality in euthyroid subjects

Roos A , Links T P , Gans R O B , Wolffenbuttel B H R , Bakker S J L

Objective: Many studies suggest that thyroid function modifies the process of healthy aging in humans. However, both a progressive increase and decrease of TSH with advancing age have been reported. The discrepancy may lie in the iodine intake in the population under, since low iodine intake results in an inverse association of TSH with age, while high iodine intake results in a positive association. We aimed to investigate whether FT4, FT3 and FT3</...

ea0029p981 | Female Reproduction | ICEECE2012

Metabolic and hormonal parameters in lean PCOS women

Dolfing J. , van Haard P. , Schweitzer D. , Wolffenbuttel B.

Background: A minority of women with polycystic ovary syndrome (PCOS) is lean, and several individuals have no signs of hyperandrogenaemia. Earlier we showed that lean PCOS patients have no increased visceral adiposity. The aim of the present study was study is to characterize the metabolic and hormonal status a group of lean PCOS cases.Methods: In this cross-sectional study ten Caucasian women with PCOS and ten controls carefully matched for age and BMI...

ea0029p352 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Successful pregnancy during use of octreotide and pegvisomant in an acromegalic patient

van der Klauw M. , van der Horst-Schrivers A. , Hoek A. , Bidlingmaier M. , Wolffenbuttel B.

Introduction: Acromegaly is preferentially treated by surgery and/or radiotherapy before pregnancy, in order to avoid use of medication during pregnancy, and prevent GH excess related complications for mother and child. Only two cases of use of pegvisomant during pregnancy have been described; in one patient medication was discontinued after the first trimester, and in the other pegvisomant was used as monotherapy.Case report: A 29-years old female had b...

ea0029p1372 | Pituitary Clinical | ICEECE2012

Effects of previous GH excess and current medical treatment for acromegaly on cognition

Brummelman P. , Koerts J. , Dullaart R. , van den Berg G. , Tucha O. , Wolffenbuttel B. , van Beek A.

Context: In untreated acromegalic patients, decreased cognitive functioning is reported to be associated with the degree of GH and IGF1 excess. Whether previous GH excess or current medical treatment for acromegaly specifically affects cognition remains unclear.Objective: To compare cognitive functioning in patients who are treated for acromegaly and non-functioning pituitary adenomas (NFA). In addition, we assessed the influence of prolonged medical tre...

ea0026p397 | Thyroid (non cancer) | ECE2011

Thyroid status and health-related quality of life in the LifeLines-cohort

Klaver E I , Stienstra R , van der Klauw M M , Kema I P , Wolffenbuttel B H R

Background: Thyroid disorders are prevalent in western society, yet many subjects experience limited symptoms at diagnosis, especially in hypothyroidism.Design: In order to compare the health-related quality of life (HR-QOL) of subjects with suppressed TSH-levels (TSH<0.5 mU/l) or elevated TSH-levels (TSH>10 mU/l) to subjects with normal TSH-levels (TSH 0.5–4 mU/l), a cross-sectional study was performed within the Dutch adult population who ...

ea0026p237 | Pituitary | ECE2011

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma M R , Netea-Maier R T , van den Berg G , Homan J , Sluiter W J , van den Bergh A C M , Wolffenbuttel B H R , Hermus A R M M , van Beek A P

Objective: To assess the influence of use of long-acting somatostatin analogs on long-term health-related quality of life (HR-QoL) in relation to disease control in patients surgically-treated for acromegaly.Design: Cross-sectional study in two University Medical Centers in The Netherlands.Patients: One hundred and eight patients (47 m/61 f, mean age 54±11 years) with a minimal follow up period of 1 year after pituitary surger...